Corcept Therapeutics vs. RenTech Picks
This is a news story, published by Yahoo Finance, that relates primarily to Jim Simons news.
Jim Simons news
For more Jim Simons news, you can click here:
more Jim Simons newsstocks trading & speculation news
For more stocks trading & speculation news, you can click here:
more stocks trading & speculation newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like stocks trading & speculation news, you might also like this article about
hedge fund. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest hedge fund space news, several hedge funds news, stocks trading & speculation news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Hedge Fund HoldersInsider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey
•Business
Business & Economics
Corcept Therapeutics (CORT): Among Billionaire Jim Simons’ RenTech’s Small-Cap Stock Picks with Huge Upside Potential

80% Informative
Billionaire Jim Simons ’ RenTech ’s 10 Small-Cap Stock Picks with Huge Upside Potential .
Renaissance Technologies ( RenTech ) began as a hedge fund but later morphed into something bigger.
It is now an investment management firm that operates several hedge funds.
At death, he was worth $31.4 billion and ranked among the top 100 richest people in the world.
Corcept Therapeutics Incorporated (NASDAQ:CORT) is making substantial progress across its clinical development pipeline.
Piper Sandler raised its price target to $ 131.00 from $ 128.00 in April 2025 .
Overall, CORT ranks 1st on our list of Billionaire Jim Simons ’ RenTech ’s small-cap stock picks.
VR Score
80
Informative language
77
Neutral language
47
Article tone
formal
Language
English
Language complexity
51
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
9
Source diversity
1
Affiliate links
no affiliate links